← Leaderboards
Min-Hao Kuo
Michigan State University
$6,829,907
Attributed
$7,750,048
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,750,048 · 10
By mechanism
R01$4,774,869 · 4
R21$1,633,842 · 4
RF1$1,337,894 · 1
P41$3,443 · 1
Top collaborators
- Chia-Yi Kuan3 shared
Most similar at Michigan State University
Same institution · by research overlap
- Karl Boynton Seydel$5,504,925
- Michael D Schwartz$1,296,986
- Kenneth C Williams$75,000
- Reginald S Sheehan$178,008
- William D Wulff$375,000
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposHyperphosphorylated TauNeurofibrillary TanglesS DiseaseTau ProteinsProteinsPathologicImpaired CognitionNeurodegenerative DisordersDrug DiscoveryRecombinantsNerve DegenerationAmericanIn VitroMolecularPhosphorylationBiochemicalTau AggregationCellsNeuronsTau-1BaseBrainDrug Development
Grant awards (22)
Treating neurotoxicity and cognitive deficits due to hyperphosphorylated tau.$603,078
R01 · FY2025 · NS
Hyperphosphorylated tau and the molecular mechanisms of tauopathy$412,095
R01 · FY2025 · AG · contact PI
Treating neurotoxicity and cognitive deficits due to hyperphosphorylated tau.$608,361
R01 · FY2024 · NS
A novel non-transgenic fly model for tauopathies$195,625
R21 · FY2024 · AG · contact PI
Treating neurotoxicity and cognitive deficits due to hyperphosphorylated tau.$628,844
R01 · FY2023 · NS
A novel non-transgenic fly model for tauopathies$234,750
R21 · FY2023 · AG · contact PI
Hyperphosphorylated tau and the molecular mechanisms of tauopathy$1,337,894
RF1 · FY2022 · AG · contact PI
Hyperphosphorylated tau aggregation-based Alzheimerâs disease early drug discovery$427,676
R01 · FY2021 · AG · contact PI
ePIMAX-RCR: Controlled expression of post-translationally modified proteins in eukaryotes$195,625
R21 · FY2021 · GM · contact PI
Hyperphosphorylated tau aggregation-based Alzheimerâs disease early drug discovery$436,696
R01 · FY2020 · AG · contact PI
ePIMAX-RCR: Controlled expression of post-translationally modified proteins in eukaryotes$234,750
R21 · FY2020 · GM · contact PI
Hyperphosphorylated tau aggregation-based Alzheimerâs disease early drug discovery$431,676
R01 · FY2019 · AG · contact PI
Delineating protein-protein interaction network of hyperphosphorylated tau in tauopathies$188,738
R21 · FY2017 · AG · contact PI
Delineating protein-protein interaction network of hyperphosphorylated tau in tauopathies$241,430
R21 · FY2016 · AG · contact PI
Hyperphosphorylated tau as drug target$161,500
R21 · FY2012 · AG · contact PI
Hyperphosphorylated tau as drug target$181,424
R21 · FY2011 · AG · contact PI
HISTONE ACETYLTRANSFERASE AND TRANSCRIPTIONAL REGULATION$248,170
R01 · FY2005 · GM
HISTONE ACETYLTRANSFERASE AND TRANSCRIPTIONAL REGULATION$248,170
R01 · FY2004 · GM
IDENTIFICATION OF ACETYLATED HISTONE BINDING PROTEINS$3,443
P41 · FY2004 · RR
HISTONE ACETYLTRANSFERASE AND TRANSCRIPTIONAL REGULATION$247,824
R01 · FY2003 · GM
HISTONE ACETYLTRANSFERASE AND TRANSCRIPTIONAL REGULATION$246,994
R01 · FY2002 · GM
HISTONE ACETYLTRANSFERASE AND TRANSCRIPTIONAL REGULATION$235,285
R01 · FY2001 · GM